Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Herbal Firm Denied Supreme Court Hearing Over Cancer Claim

This article was originally published in The Tan Sheet

Executive Summary

The Supreme Court will not consider herbal supplement marketer Daniel Chapter One's argument that the right to freedom of religion allows the firm to claim its products cure cancer.

You may also be interested in...



Yohimbe Ban Suggested, 'God' Warned: Health And Wellness Industry News

ED-spiked supplement importers identified; FDA and FTC act on GAO outreach suggestion; ephedra-like rulemaking needed for yohimbe – study; and God's book among violative claims by Florida firm.

Enforcement Roundup: Daniel Chapter One, Peanut Corp. Of America

Final chapter for Daniel Chapter One owner; prison sentence for head of salmonella-tainted peanut firm.

Enforcement Roundup: Daniel Chapter One, Peanut Corp. Of America

Final chapter for Daniel Chapter One owner; prison sentence for head of salmonella-tainted peanut firm.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS105082

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel